Albuquerque Juliana Costa, Magalhães Rosane Aline, Félix Jamille Araújo, Bastos Maria Vilani Rodrigues, Fontenele Juvenia Bezerra, Trompieri Nádia Mendonça, Felix Francisco Helder Cavalcante
Universidade Federal do Ceará, FortalezaCeará, Brazil, Pharmacy Student, Universidade Federal do Ceará (UFC), Fortaleza, Ceará, Brazil.
Department of Pharmacology and Physiology, Universidade Federal do Ceará, FortalezaCeará, Brazil, Employee of the Department of Pharmacology and Physiology, Universidade Federal do Ceará (UFC), Fortaleza, Ceará, Brazil.
Sao Paulo Med J. 2014;132(1):48-54. doi: 10.1590/1516-3180.2014.1321575.
Hemangiomas are the commonest vascular tumors during childhood. In 2008, the effect of propranolol for treating capillary hemangiomas was demonstrated. Other similar results followed, showing that it rapidly reduces lesion volume. The objective here was to evaluate children and adolescents with hemangiomas that were treated with propranolol.
Retrospective study, conducted in a children's hospital.
Patients aged 0-19 years with or without previous treatment, who were treated between January 2009 and December 2010, were included. The response was assessed by comparing the lesion appearance between the start of treatment and the last consultation. We considered partial or complete responses as the response to treatment.
Sixty-nine patients with a median follow-up of 11 months (mean age: 31 months) were included. Of these, 58 patients were recently diagnosed and 11 had had previous treatment. A response (partial or complete) was seen in 60 patients (87%). Among the capillary hemangioma cases, responses were seen in 50 out of 53 (94%), while in other lesion types, it was 10 out of 16 (63%) (P = 0.3; chi-square). Responses in patients less than one year of age were seen in 37 out of 38 (97%), whereas in those over one year of age, in 23 out of 31 (74%) (P = 0.4; chi-square). Side effects were uncommon and mild.
Propranolol seemed to be effective for treatment of hemangiomas in children and adolescents, and not just in the proliferative stage, with responses in almost all the patients.
血管瘤是儿童期最常见的血管肿瘤。2008年，证实了普萘洛尔治疗毛细血管瘤的效果。随后有其他类似结果，表明其能迅速减小病变体积。本研究的目的是评估接受普萘洛尔治疗的血管瘤患儿及青少年。
在一家儿童医院进行的回顾性研究。
纳入2009年1月至2010年12月期间接受治疗的0至19岁患者，无论其是否曾接受过治疗。通过比较治疗开始时与最后一次会诊时的病变外观来评估疗效。我们将部分或完全缓解视为治疗有效。
纳入69例患者，中位随访时间为11个月（平均年龄：31个月）。其中，58例为近期诊断，11例曾接受过治疗。60例患者（87%）出现缓解（部分或完全缓解）。在毛细血管瘤病例中，53例中有50例（94%）出现缓解，而在其他病变类型中，16例中有10例（63%）（P = 0.3；卡方检验）。1岁以下患者中，38例中有37例（97%）出现缓解，而1岁以上患者中，31例中有23例（74%）（P = 0.4；卡方检验）。副作用不常见且轻微。
普萘洛尔似乎对儿童和青少年血管瘤的治疗有效，不仅在增殖期有效，几乎所有患者均有反应。
